International Biotechnology Trust PLCLSE: IBT

International Biotechnology Trust: Net Asset Value(s)

· Issued by International Biotechnology Trust PLC via RNS

Summary by 6ix AI

International Biotechnology Trust PLC reported its unaudited net asset value (NAV) per share as at Thursday, October 8, 2026: 1103.90 pence on an ex income basis and 1063.70 pence on a cum income basis.

Key details

  • Ex income and cum income are two ways of stating NAV that differ in how income is treated.
  • The NAVs were calculated in accordance with the recommendations of the Association of Investment Companies.

6ix AI wrote this summary from the release below and checked it against the release.

International Biotechnology Trust's next earnings callInternational Biotechnology Trust (LSE:IBT) — Investor Presentation · Nov 3, 2026 at 9:00 AM ESTRegister
Intl. Biotechnology Trust PLC
09 October 2026
 
   
International Biotechnology Trust plc
Net Asset Values
   
The Board of International Biotechnology Trust PLC (the "Company") announces the unaudited net asset value ("NAV") per share of the Company as follows:
   
  Date   NAV   Pence
  Thursday 08 Oct   Ex Income   1103.90
  Thursday 08 Oct   Cum Income   1063.70
   
   
The above NAVs have been calculated in accordance with the recommendations of the Association of Investment Companies.
   
   
09-Oct-2026  
   
   
   
Enquiries:  
International Biotechnology Trust plc  
Schroder Investment Management Limited  
Company Secretary 0207 658 6501  
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

International Biotechnology Trust PLC on 6ix

Earlier from International Biotechnology Trust

Later from International Biotechnology Trust

All International Biotechnology Trust news releases